Expertise in
25
conditions

Dr. Wael A. Harb

Oncology
Office
1441 Avocado Ave Ste 301, 
Newport Beach, CA 
Expertise in
25
conditions
Office
1441 Avocado Ave Ste 301, 
Newport Beach, CA 

Overview

Wael Harb is an Oncologist practicing medicine in Newport Beach, California.

Dr. Harb is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Breast Cancer, Familial Colorectal Cancer, and Colorectal Cancer.

He is actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 15 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in IN

Hospital Affiliations

Memorialcare Orange Coast Medical Center
Memorialcare Saddleback Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Office
1441 Avocado Ave Ste 301, Newport Beach, CA 92660

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Apilimod, Rituximab, Atezolizumab
Study Phase: Phase 1
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Pembrolizumab, Rituximab
Study Phase: Phase 1
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 3
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors
A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors
Enrollment Status: Unknown
Publish Date: May 15, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors
A Phase 1 Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 12, 2022
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

29 Total Publications

Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
Journal: Leukemia & lymphoma
Published: January 23, 2024
Similar Doctors
Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

City Of Hope Orange County Lennar Foundation Cancer Center

Irvine, CA 
 (8.5 miles away)
844-975-4048
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tanya Siddiqi is an Oncologist practicing medicine in Irvine, California. Dr. Siddiqi is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Expertise in
29
conditions
Dr. Jaime Landman
Oncology | Urology
Expertise in
29
conditions
Dr. Jaime Landman
Oncology | Urology
Referral may be required

UCI Health Newport - Birch Street

20350 Southwest Birch Street, Suite 210, 
Newport Beach, CA 
 (0.1 miles away)
714-456-7005
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Dr. Jaime Landman, director of the UCI HealthCenter for Urological Care, is an internationally recognized urologist and expert in diseases and conditions of the kidneys, including kidney stones and benign and malignant tumors. He is experienced in all forms of minimally invasive kidney surgery, including robot-assisted surgery and percutaneous cryoablation.Landman, who founded the UCI HealthAblative Oncology Center,has performed thousands of advanced minimally invasive kidney procedures. He is dedicated to improving the techniques and technology associated with minimally invasive surgery.The author of more than 185 peer-reviewed articles and more than 60 book chapters, Landman has lectured around the world on the subject of minimally invasive urology. His research interests are in kidney cancer outcomes, kidney ablation and kidney imaging technologies, as well as preserving kidney function.His research efforts have helped define many of the minimally invasive kidney procedures performed today, earning him the 2005 Arthur Smith prize for creativity and dynamic innovation at the World Congress of Endourology. His clinical interests include all aspects of minimally invasive urologic oncology, with special emphasis on kidney cancer and kidney stone disease. Dr. Landman is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Kidney Stones, Renal Cell Carcinoma (RCC), Ureterocele, Lithotripsy, and Nephrectomy. Dr. Landman is board certified in American Board Of Urology - Urology.

Expertise in
19
conditions
Dr. Krishnansu S. Tewari
Oncology | Obstetrics and Gynecology
Expertise in
19
conditions
Dr. Krishnansu S. Tewari
Oncology | Obstetrics and Gynecology
Referral may be required
Before you request

UC Irvine Medical Center

101 The City Drive South, Building 29, 
Orange, CA 
 (10.6 miles away)
714-456-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Krishnansu Tewari is an Oncologist and an Obstetrics and Gynecologist practicing medicine in Orange, California. Dr. Tewari is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Lymphadenectomy. Dr. Tewari is board certified in American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology and American Board Of Obstetrics And Gynecology - Gynecologic Oncology. Dr. Tewari is currently accepting new patients.

Frequently Asked Questions about Dr. Wael A. Harb

How do I make an appointment with Dr. Wael A. Harb?

You can book an appointment with Dr. Wael A. Harb by calling their office at 657-241-9805. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Wael A. Harb a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Wael A. Harb is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Wael A. Harb specialize in?

While Dr. Wael A. Harb is a Oncology, they have specific expertise in Lung Cancer, Breast Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Wael A. Harb participate in research or clinical trials?

Yes. Dr. Wael A. Harb has published 29 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Wael A. Harb's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Wael A. Harb accept my insurance?

Dr. Wael A. Harb accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 657-241-9805 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Harb's expertise for a condition
ConditionClose
    View All 24 Advanced Conditions
    View All 74 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile